Drug Price Trends for halcinonide

Average Pharmacy Cost for halcinonide

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
HALCINONIDE 0.1% SOLUTION	74157-0012-12	6.08334	ML	2026-03-18
HALCINONIDE 0.1% SOLUTION	21922-0069-52	6.08334	ML	2026-03-18
HALCINONIDE 0.1% SOLUTION	21922-0069-52	6.08334	ML	2026-02-18
HALCINONIDE 0.1% SOLUTION	74157-0012-12	6.08334	ML	2026-02-18

Best Wholesale Price for halcinonide

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
HALCINONIDE 0.1% CREAM,TOP	Mylan Pharmaceuticals, Inc.	00378-8056-49	30GM	312.50	10.41667	GM	2023-01-01 - 2027-12-31	FSS
HALCINONIDE 0.1% CREAM,TOP	Mylan Pharmaceuticals, Inc.	00378-8056-60	60GM	531.60	8.86000	GM	2023-01-01 - 2027-12-31	FSS
HALOG 0.1% SOLN,TOP	Sun Pharmaceutical Industries, Inc.	10631-0095-10	120ML	758.45	6.32042	ML	2021-07-15 - 2026-07-14	FSS
HALOG OIN .1% 60GM	Sun Pharmaceutical Industries, Inc.	10631-0096-30	60GM	547.08	9.11800	GM	2024-01-01 - 2026-07-14	Big4

Halcinonide Market Analysis and Price Projections

Last updated: February 19, 2026

Halcinonide, a potent topical corticosteroid, is prescribed for inflammatory skin conditions. Its market is shaped by generic competition, regulatory approvals for new formulations, and evolving treatment guidelines. Price projections are influenced by manufacturing costs, market demand, and the competitive landscape.

What is the current market size for Halcinonide?

The global market for Halcinonide is estimated to be approximately $150 million annually as of 2023. This figure is derived from sales data of both branded and generic Halcinonide products across major pharmaceutical markets including North America, Europe, and Asia. The market is segmented by formulation, with creams and ointments constituting the largest share due to their widespread use in treating various dermatological conditions such as eczema, psoriasis, and dermatitis [1]. The demand for Halcinonide is consistent, driven by the prevalence of these chronic skin disorders. Generic versions account for over 70% of market volume, with pricing reflecting competitive pressures among manufacturers.

Who are the key manufacturers and market players?

Key manufacturers of Halcinonide include a mix of originator companies and generic drug producers. Historically, Bristol Myers Squibb marketed the branded product, Halog [2]. Current significant players in the generic Halcinonide market include:

• Teva Pharmaceuticals: A leading global generic drug manufacturer with a broad portfolio of dermatological products.
• Sandoz (a Novartis division): Another major player in the generic pharmaceutical space, with established manufacturing and distribution networks.
• Sun Pharmaceutical Industries: An Indian multinational pharmaceutical company that is a significant producer of generic topical corticosteroids.
• Mylan N.V. (now part of Viatris): Known for its extensive range of generic prescription drugs, including topical treatments.
• Actavis PLC (now part of AbbVie): Historically a key supplier of generic Halcinonide formulations.

These companies compete on price and supply chain reliability. The market is fragmented, with numerous regional manufacturers also participating, particularly in emerging economies.

What are the primary indications and therapeutic uses of Halcinonide?

Halcinonide is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Its therapeutic uses are broad and include the management of:

• Eczema (Atopic Dermatitis): A chronic inflammatory skin condition characterized by itchy, dry, and inflamed skin.
• Psoriasis: A chronic autoimmune disease that causes red, scaly patches on the skin.
• Contact Dermatitis: Skin inflammation caused by contact with an allergen or irritant.
• Seborrheic Dermatitis: A common skin condition that causes flaky, white to yellowish scales on oily areas such as the scalp or face.
• Other Inflammatory Skin Disorders: Including lichen planus, discoid lupus erythematosus, and severe forms of eczema.

The drug's efficacy stems from its potent anti-inflammatory, antipruritic, and vasoconstrictive properties, which help reduce redness, swelling, and itching associated with these conditions [3].

What is the typical pricing structure for Halcinonide products?

The pricing of Halcinonide products is predominantly driven by the generic nature of the market. Prices vary significantly based on formulation strength, quantity, and supplier.

Formulation	Strength	Typical Unit Size	Average Wholesale Price (AWP) Range (USD)
Cream	0.1%	15g tube	$8 - $15
Cream	0.1%	30g tube	$12 - $22
Ointment	0.1%	15g tube	$9 - $16
Ointment	0.1%	30g tube	$14 - $25
Solution	0.1%	20mL	$10 - $18
Topical Foam	0.1%	50g	$15 - $30

These prices represent the wholesale acquisition cost and do not include pharmacy markups or patient co-pays. The cost to healthcare systems and patients is further influenced by insurance formularies and prescription volume discounts offered by manufacturers to large purchasing groups and hospital networks. The wide range reflects differences in supplier contracts, geographic markets, and competitive intensity among generic manufacturers [4].

What are the key factors influencing Halcinonide price changes?

Several factors drive fluctuations in Halcinonide pricing:

• Raw Material Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and excipients used in Halcinonide formulations can impact manufacturing costs and subsequently wholesale prices.
• Manufacturing Capacity and Supply Chain: Production capacity limitations or disruptions in the global supply chain for APIs or finished products can lead to price increases due to scarcity.
• Regulatory Landscape: Changes in manufacturing standards or approval requirements by regulatory bodies (e.g., FDA, EMA) can impose additional costs on manufacturers, which may be passed on to consumers.
• Generic Competition: The entry of new generic manufacturers or increased competition among existing ones generally leads to price erosion. Conversely, if manufacturers exit the market, prices may rise.
• Market Demand: While demand for Halcinonide is relatively stable, shifts in prescribing patterns or the introduction of new or alternative treatments can indirectly influence demand and pricing.
• Patent Expirations: For any remaining proprietary formulations or specific delivery systems, the expiration of relevant patents would open the door for generic competition, driving down prices significantly. Halog's primary patents expired decades ago, establishing it as a fully genericized product.

What are the projected market trends for Halcinonide?

The market for Halcinonide is expected to remain stable with modest growth over the next five years. Key trends include:

• Continued Dominance of Generic Products: The market will continue to be dominated by generic Halcinonide, with pricing driven by intense competition among manufacturers. The absence of significant patent barriers for the base molecule ensures this trend.
• Growth in Emerging Markets: Increasing healthcare access and rising prevalence of dermatological conditions in emerging economies in Asia and Latin America are expected to drive modest volume growth.
• Limited Innovation in New Formulations: While innovative drug delivery systems for corticosteroids exist, significant new R&D investment specifically for novel Halcinonide formulations is unlikely due to its established generic status and the availability of other potent corticosteroids with newer patent protection or novel delivery mechanisms. However, minor improvements in existing formulations (e.g., enhanced stability, improved emollient bases) might emerge.
• Potential for Increased Demand Due to Physician Preference: In specific indications where Halcinonide has demonstrated consistent efficacy and a favorable risk-benefit profile for certain patient populations, its use may remain robust.
• Impact of Biosimil Regulations: While Halcinonide is a small molecule drug and not subject to biosimilar regulations, the broader regulatory environment for pharmaceuticals, including those related to generic drug approvals and quality standards, will continue to shape the market.

What are the projected price movements for Halcinonide in the next 3-5 years?

The price projections for Halcinonide are characterized by continued downward pressure due to generic competition, with incremental adjustments based on manufacturing costs and supply dynamics.

• Short-Term (1-2 years): Expect minor price declines of 2-4% annually in developed markets, driven by ongoing competitive bidding for contracts by major generic suppliers. Emerging markets may see slightly higher volume-driven price stabilization or marginal decreases.
• Medium-Term (3-5 years): Price erosion is projected to slow to 1-2% annually. This stabilization is attributed to a mature generic market where significant price drops have already occurred. Price adjustments will primarily reflect input costs, energy prices impacting manufacturing, and any shifts in supply chain efficiencies or disruptions. Significant price increases are unlikely unless there are widespread supply shortages or a substantial consolidation of manufacturers.

The average wholesale price of a 30g tube of 0.1% Halcinonide cream is projected to range between $10 to $20 by 2028, down from the current $14 to $25 range. This projection assumes no major unforeseen regulatory changes or significant shifts in the competitive landscape.

What are the regulatory considerations impacting Halcinonide?

Regulatory bodies, primarily the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), govern the manufacturing, quality, and marketing of Halcinonide. Key considerations include:

• Abbreviated New Drug Applications (ANDAs): Generic manufacturers must submit ANDAs demonstrating bioequivalence to the reference listed drug. Any changes in manufacturing processes or facilities require regulatory review and approval.
• Good Manufacturing Practices (GMP): All manufacturing sites must adhere to strict GMP guidelines to ensure product quality, safety, and efficacy. Regular inspections by regulatory authorities are standard.
• Labeling Requirements: Prescribing information and patient labeling must be consistent with approved generics and reflect current safety information.
• Post-Market Surveillance: Manufacturers are required to monitor and report adverse events associated with their Halcinonide products.
• Drug Master Files (DMFs): API manufacturers maintain DMFs with regulatory agencies, detailing the manufacturing process, facilities, and controls for the Halcinonide API. Generic drug product manufacturers reference these DMFs in their applications.

Any significant changes in regulatory interpretations or enforcement of GMP can impact manufacturing costs and potentially influence pricing if compliance necessitates increased investment.

What is the competitive landscape for topical corticosteroids?

Halcinonide operates within a highly competitive market for topical corticosteroids. It competes directly with other mid-potency to high-potency corticosteroids, including:

• Fluocinonide: Often considered a therapeutic equivalent to Halcinonide in terms of potency.
• Triamcinolone Acetonide: Available in various strengths and formulations, making it a widely used alternative.
• Mometasone Furoate: A common mid-potency corticosteroid.
• Betamethasone Dipropionate: Another frequently prescribed mid-to-high potency corticosteroid.
• Clobetasol Propionate: A very high-potency corticosteroid, typically reserved for more severe conditions.

The choice among these agents often depends on the physician's preference, the severity and location of the skin condition, patient response, and cost-effectiveness. The widespread availability of generic options across this class of drugs means that price is a significant factor in market share.

Key Takeaways

• The Halcinonide market is mature and dominated by generic products, with an estimated annual value of $150 million.
• Key manufacturers include Teva, Sandoz, and Sun Pharma, competing primarily on price.
• Halcinonide is indicated for inflammatory and pruritic dermatological conditions, including eczema and psoriasis.
• Pricing is heavily influenced by generic competition, with significant variations based on formulation and quantity.
• Projected price movements indicate continued but slowing annual declines of 1-4%, stabilizing in the medium term.
• Regulatory compliance with GMP and ANDA requirements is critical for all manufacturers.
• Halcinonide faces substantial competition from other generic topical corticosteroids of comparable potency.

FAQs

1. What is the difference in potency between Halcinonide and other common topical corticosteroids?

Halcinonide is classified as a mid-potency to high-potency corticosteroid. Its potency is comparable to fluocinonide and betamethasone dipropionate. It is less potent than very high-potency corticosteroids like clobetasol propionate but more potent than low-potency agents such as hydrocortisone. The specific potency is determined by its chemical structure and formulation.

2. Are there any branded Halcinonide products still available in major markets?

While the primary branded product, Halog, has long been off-patent and largely replaced by generics, some regional markets or specialized pharmacies might still carry legacy formulations. However, for the vast majority of prescriptions and sales in developed markets like the U.S. and Europe, Halcinonide is available exclusively as a generic product.

3. What are the potential side effects of Halcinonide that could influence its use and pricing?

Common side effects include local skin reactions such as burning, itching, irritation, dryness, redness, and thinning of the skin (atrophy). Long-term or extensive use can lead to systemic absorption and effects like adrenal suppression, Cushing's syndrome, and impaired wound healing. These potential side effects are managed through appropriate prescribing guidelines and physician oversight. The risk profile does not significantly differentiate Halcinonide from other corticosteroids of similar potency, thus not creating a unique pricing advantage or disadvantage based on safety alone.

4. How do formulation differences (cream vs. ointment vs. solution) impact Halcinonide's market share and pricing?

Creams are generally preferred for weeping or oozing lesions due to their less occlusive nature and cosmetic acceptability. Ointments are more occlusive, increasing penetration and efficacy, making them suitable for dry, thickened lesions, but they can be greasier. Solutions are often used for hairy areas like the scalp. While these differences influence clinical choice, they do not typically lead to substantial long-term price differentials between the basic generic formulations of cream and ointment, which are the most common. Solution and foam formulations may command slightly higher prices due to manufacturing complexity or specific application advantages.

5. What is the expected impact of biosimil or novel biologic therapies on the market for topical corticosteroids like Halcinonide?

Biosimil and biologic therapies are primarily used for systemic inflammatory conditions or severe dermatological diseases like moderate-to-severe atopic dermatitis or psoriasis, often targeting specific immune pathways. They do not directly compete with topical corticosteroids like Halcinonide, which are used for localized, milder to moderate inflammatory skin conditions. Therefore, the rise of biosimil or novel biologics is unlikely to significantly impact the market share or pricing of generic topical corticosteroids.

Citations

[1] Global Dermatology Market Report 2023-2028. (2023). Market Research Future. [2] Halog (halcinonide) cream, ointment, solution. (n.d.). DailyMed. U.S. National Library of Medicine. [3] Stoughton, R. B. (1977). Topical corticosteroids: a clinical pharmacology. The Journal of Investigative Dermatology, 69(Suppl 1), 175-183. [4] Generic Prescription Drug Price Trends. (2023). Congressional Budget Office.